Department of Clinical Medicine and Surgery (B.B.), University of Naples Federico II, 80131 Naples, Italy; and Washington Hospital Center (L.W.), Washington, D.C. 20010.
Endocr Rev. 2014 Jun;35(3):433-512. doi: 10.1210/er.2013-1083. Epub 2014 Jan 16.
Thyroid hormone deficiency can have important repercussions. Treatment with thyroid hormone in replacement doses is essential in patients with hypothyroidism. In this review, we critically discuss the thyroid hormone formulations that are available and approaches to correct replacement therapy with thyroid hormone in primary and central hypothyroidism in different periods of life such as pregnancy, birth, infancy, childhood, and adolescence as well as in adult patients, the elderly, and in patients with comorbidities. Despite the frequent and long term use of l-T4, several studies have documented frequent under- and overtreatment during replacement therapy in hypothyroid patients. We assess the factors determining l-T4 requirements (sex, age, gender, menstrual status, body weight, and lean body mass), the major causes of failure to achieve optimal serum TSH levels in undertreated patients (poor patient compliance, timing of l-T4 administration, interferences with absorption, gastrointestinal diseases, and drugs), and the adverse consequences of unintentional TSH suppression in overtreated patients. Opinions differ regarding the treatment of mild thyroid hormone deficiency, and we examine the recent evidence favoring treatment of this condition. New data suggesting that combined therapy with T3 and T4 could be indicated in some patients with hypothyroidism are assessed, and the indications for TSH suppression with l-T4 in patients with euthyroid multinodular goiter and in those with differentiated thyroid cancer are reviewed. Lastly, we address the potential use of thyroid hormones or their analogs in obese patients and in severe cardiac diseases, dyslipidemia, and nonthyroidal illnesses.
甲状腺激素缺乏会产生重要影响。对于甲状腺功能减退症患者,甲状腺激素替代治疗至关重要。在这篇综述中,我们批判性地讨论了现有的甲状腺激素制剂以及在不同生命阶段(如妊娠、分娩、婴儿期、儿童期和青春期)以及成年患者、老年人和合并症患者中纠正原发性和中枢性甲状腺功能减退症的甲状腺激素替代治疗的方法。尽管 l-T4 经常且长期使用,但多项研究记录了甲状腺功能减退症患者在替代治疗期间经常出现治疗不足和过度治疗的情况。我们评估了决定 l-T4 需求的因素(性别、年龄、性别、月经状况、体重和去脂体重)、未接受治疗的患者未能达到最佳血清 TSH 水平的主要原因(患者依从性差、l-T4 给药时间、吸收干扰、胃肠道疾病和药物)以及治疗不足的患者 TSH 抑制的不良后果。对于轻度甲状腺激素缺乏症的治疗意见不一,我们审查了支持治疗这种情况的最新证据。评估了表明在某些甲状腺功能减退症患者中联合使用 T3 和 T4 可能是指征的新数据,并审查了 l-T4 抑制 TSH 在甲状腺功能正常多结节性甲状腺肿患者和分化型甲状腺癌患者中的适应证。最后,我们讨论了在肥胖患者和严重心脏疾病、血脂异常和非甲状腺疾病患者中使用甲状腺激素或其类似物的潜在用途。